Arcus Biosciences Inc (RCUS)

$25.36 +0.58 (2.34%)
Market Cap 3.19B
Revenue (ttm) 247.00M
Net Income (ttm) -353.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -142.92%
Debt to Equity Ratio 0.16
Volume 967,700
Avg Vol 1,297,500
Day's Range N/A - N/A
Shares Out 125.77M
Stochastic %K 52%
Beta 0.87
Analysts Strong Sell
Price Target $34.40

Company Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD7...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 694 6200
Address:
3928 Point Eden Way, Hayward, United States
ACES_
ACES_ May. 6 at 12:44 AM
$RCUS Focused management is a good thing. Cash is a good thing.
0 · Reply
Theobviouschoice
Theobviouschoice May. 5 at 8:43 PM
$RCUS Nonsense 2 shares drop the sp 😠
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 8:14 PM
$RCUS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.02 up 10.53% YoY • Reported revenue of $17M down -39.29% YoY • Arcus Biosciences believes its $876M in cash, cash equivalents, and marketable securities as of March 31, 2026, will fund planned operations until at least the second half of 2028.
0 · Reply
bryantboy99
bryantboy99 May. 5 at 10:30 AM
$RCUS https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2026/Arcus-Biosciences-to-Host-Conference-Call-to-Discuss-First-Quarter-2026-Financial-Results-and-Pipeline-Updates/default.aspx
0 · Reply
VAK7
VAK7 May. 5 at 3:36 AM
$HOOD $KRYS $NBIS $RCUS $TGTX That was a very nice summary. And picks. And set me up for 75% 1 yeah performance since 5/4/25. TGTX and HOOD are lagging from this cohort of 5. But not for long. Imho TGTX will be over $45 this year; and HOOD will be in triple digits, no doubt about it. I could have done better, but, to my defense, MW should have sold TGTX before summer 2025; I told myself that if he does not do that, or buy out EU rights, i will reduce my TGTX position before 2 year term to buyback EU rights lapses. And I did not. Price you pay for your own indecisiveness.
0 · Reply
bryantboy99
bryantboy99 May. 1 at 3:18 PM
$AUPH Come on Kevin, we need to get back on track and join my other bio's going to the moon $ETON and $RCUS while I patiently wait for $CTMX to catch up.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 1 at 1:35 AM
$RCUS RSI: 63.04, MACD: 0.8259 Vol: 1.30, MA20: 23.82, MA50: 22.49 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LiveCommander
LiveCommander Apr. 22 at 11:04 PM
$RCUS nice breakout
0 · Reply
JazzyJ03
JazzyJ03 Apr. 22 at 3:19 PM
$RCUS
0 · Reply
bryantboy99
bryantboy99 Apr. 22 at 3:08 PM
$AUPH Come on Tang, gonna need Auph to catch up to $RCUS if you don't mind.
0 · Reply
Latest News on RCUS
Arcus Biosciences Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 5 days ago

Arcus Biosciences Earnings Call Transcript: Q1 2026

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

May 5, 2026, 4:05 PM EDT - 5 days ago

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants

Apr 24, 2026, 4:05 PM EDT - 16 days ago

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences rises 12.2%

2026-04-22T15:01:23.000Z - 18 days ago

Arcus Biosciences rises 12.2%

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates

Apr 21, 2026, 4:05 PM EDT - 19 days ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates

Merck setback has positives and negatives for Arcus Biosciences, says BofA

2026-04-21T16:16:40.000Z - 19 days ago

Merck setback has positives and negatives for Arcus Biosciences, says BofA

MRK

Merck study miss not a read for Arcus, says H.C. Wainwright

2026-04-21T16:11:24.000Z - 19 days ago

Merck study miss not a read for Arcus, says H.C. Wainwright

MRK

Arcus Biosciences discontinues Star-121 study with Gilead due to futility

2026-04-20T19:05:48.000Z - 20 days ago

Arcus Biosciences discontinues Star-121 study with Gilead due to futility

GILD

Arcus Biosciences price target lowered to $47 from $49 at Leerink

2026-04-20T18:55:13.000Z - 20 days ago

Arcus Biosciences price target lowered to $47 from $49 at Leerink

GILD

Wedbush raises Arcus Biosciences price target to $41, adds to Best Ideas List

2026-04-02T13:12:42.000Z - 5 weeks ago

Wedbush raises Arcus Biosciences price target to $41, adds to Best Ideas List

Arcus Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 11:20 AM EDT - 2 months ago

Arcus Biosciences Transcript: Leerink Global Healthcare Conference 2026

Arcus Biosciences price target raised to $45 from $44 at Citi

2026-03-05T11:38:20.000Z - 2 months ago

Arcus Biosciences price target raised to $45 from $44 at Citi

Arcus Biosciences price target raised to $49 from $36 at Leerink

2026-03-02T11:10:31.000Z - 2 months ago

Arcus Biosciences price target raised to $49 from $36 at Leerink

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Feb 26, 2026, 4:05 PM EST - 2 months ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences reports Q4 EPS (89c), consensus ($1.08)

2026-02-25T21:54:43.000Z - 2 months ago

Arcus Biosciences reports Q4 EPS (89c), consensus ($1.08)

Arcus Biosciences files automatic mixed securities shelf

2026-02-25T21:41:45.000Z - 2 months ago

Arcus Biosciences files automatic mixed securities shelf

Arcus Biosciences Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 2 months ago

Arcus Biosciences Earnings Call Transcript: Q4 2025

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

Feb 25, 2026, 4:05 PM EST - 2 months ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

Arcus Biosciences’ casdatifan shows increased survival in kidney cancer

2026-02-23T22:10:16.000Z - 2 months ago

Arcus Biosciences’ casdatifan shows increased survival in kidney cancer

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

Feb 23, 2026, 5:00 PM EST - 2 months ago

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo

2026-02-12T10:20:13.000Z - 3 months ago

Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo

EXEL

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

Feb 11, 2026, 4:05 PM EST - 3 months ago

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

Arcus Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:00 PM EST - 4 months ago

Arcus Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Arcus Biosciences upgraded to Buy from Neutral at Goldman Sachs

2026-01-12T21:30:13.000Z - 4 months ago

Arcus Biosciences upgraded to Buy from Neutral at Goldman Sachs

Arcus Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley

2026-01-08T10:05:26.000Z - 4 months ago

Arcus Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley

Arcus sees at least three casdatifan data readouts in 2026

2026-01-07T21:10:31.000Z - 4 months ago

Arcus sees at least three casdatifan data readouts in 2026

Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs

Jan 7, 2026, 4:05 PM EST - 4 months ago

Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs

Arcus Biosciences falls -9.2%

2026-01-05T17:07:09.000Z - 4 months ago

Arcus Biosciences falls -9.2%

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 4:05 PM EST - 5 months ago

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

Dec 12, 2025, 8:30 AM EST - 5 months ago

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

Arcus Biosciences Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 10:30 AM EST - 5 months ago

Arcus Biosciences Transcript: Citi Annual Global Healthcare Conference 2025

Arcus Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 4:40 PM EST - 5 months ago

Arcus Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Oct 30, 2025, 11:35 PM EDT - 6 months ago

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Oct 30, 2025, 4:01 PM EDT - 6 months ago

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Oct 28, 2025, 4:05 PM EDT - 6 months ago

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

Oct 19, 2025, 7:00 PM EDT - 7 months ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Oct 12, 2025, 6:05 PM EDT - 7 months ago

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Arcus Biosciences Transcript: R&D Day 2025

Oct 6, 2025, 10:00 AM EDT - 7 months ago

Arcus Biosciences Transcript: R&D Day 2025

Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event

Oct 6, 2025, 8:00 AM EDT - 7 months ago

Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event

Arcus Biosciences Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 8:30 AM EDT - 8 months ago

Arcus Biosciences Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Arcus Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 8:00 AM EDT - 8 months ago

Arcus Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Arcus Biosciences Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 11:15 AM EDT - 8 months ago

Arcus Biosciences Transcript: Citi's Biopharma Back to School Conference

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

Sep 2, 2025, 4:05 PM EDT - 8 months ago

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Aug 20, 2025, 4:05 PM EDT - 9 months ago

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

Aug 6, 2025, 4:05 PM EDT - 9 months ago

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

Jul 10, 2025, 8:30 AM EDT - 10 months ago

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

Arcus Biosciences Transcript: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arcus Biosciences Transcript: Study Update

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

Jun 1, 2025, 10:45 AM EDT - 1 year ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

Arcus Biosciences Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcus Biosciences Earnings Call Transcript: Q1 2025

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

May 6, 2025, 4:05 PM EDT - 1 year ago

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Arcus Biosciences Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Arcus Biosciences Transcript: Barclays 27th Annual Global Healthcare Conference

Arcus Biosciences Transcript: Leerink’s Global Healthcare Conference 2025

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Arcus Biosciences Transcript: Leerink’s Global Healthcare Conference 2025

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Feb 25, 2025, 4:05 PM EST - 1 year ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences Transcript: Status Update

Feb 18, 2025, 8:00 AM EST - 1 year ago

Arcus Biosciences Transcript: Status Update

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Feb 18, 2025, 6:57 AM EST - 1 year ago

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Feb 18, 2025, 6:52 AM EST - 1 year ago

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Feb 15, 2025, 3:45 PM EST - 1 year ago

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Feb 10, 2025, 5:00 PM EST - 1 year ago

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Jan 21, 2025, 4:05 PM EST - 1 year ago

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Arcus Biosciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 6:45 PM EST - 1 year ago

Arcus Biosciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 4:05 PM EST - 1 year ago

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Arcus Biosciences Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 7:55 AM EST - 1 year ago

Arcus Biosciences Transcript: 7th Annual Evercore ISI HealthCONx Conference

Arcus Biosciences Earnings Call Transcript: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Arcus Biosciences Earnings Call Transcript: Q3 2024

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Nov 6, 2024, 4:22 PM EST - 1 year ago

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Nov 5, 2024, 9:00 AM EST - 1 year ago

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Oct 30, 2024, 9:00 AM EDT - 1 year ago

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Arcus Biosciences Transcript: Study Update

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Arcus Biosciences Transcript: Study Update

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Oct 24, 2024, 7:30 AM EDT - 1 year ago

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

AZN

Arcus Biosciences Transcript: 2024 Cantor Global Healthcare Conference

Sep 19, 2024, 10:55 AM EDT - 1 year ago

Arcus Biosciences Transcript: 2024 Cantor Global Healthcare Conference

Arcus Biosciences Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 10:55 AM EDT - 1 year ago

Arcus Biosciences Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Arcus Biosciences Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 4:50 PM EDT - 1 year ago

Arcus Biosciences Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

HTGC

Arcus Biosciences Earnings Call Transcript: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 1 year ago

Arcus Biosciences Earnings Call Transcript: Q2 2024

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Jul 25, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Jul 8, 2024, 6:00 PM EDT - 1 year ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Arcus Biosciences Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 12, 2024, 10:00 AM EDT - 2 years ago

Arcus Biosciences Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Jun 10, 2024, 8:30 AM EDT - 2 years ago

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 4:05 PM EDT - 2 years ago

Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

Jun 2, 2024, 8:00 AM EDT - 2 years ago

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

GILD

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

Jun 1, 2024, 8:00 AM EDT - 2 years ago

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

GILD

Arcus Biosciences Transcript: BofA Securities 2024 Health Care Conference

May 16, 2024, 1:00 PM EDT - 2 years ago

Arcus Biosciences Transcript: BofA Securities 2024 Health Care Conference

Arcus Biosciences Earnings Call Transcript: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Arcus Biosciences Earnings Call Transcript: Q1 2024

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update

May 8, 2024, 4:02 PM EDT - 2 years ago

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024

May 2, 2024, 4:05 PM EDT - 2 years ago

Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Apr 24, 2024, 4:00 PM EDT - 2 years ago

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

Apr 23, 2024, 4:05 PM EDT - 2 years ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

ACES_
ACES_ May. 6 at 12:44 AM
$RCUS Focused management is a good thing. Cash is a good thing.
0 · Reply
Theobviouschoice
Theobviouschoice May. 5 at 8:43 PM
$RCUS Nonsense 2 shares drop the sp 😠
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 8:14 PM
$RCUS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.02 up 10.53% YoY • Reported revenue of $17M down -39.29% YoY • Arcus Biosciences believes its $876M in cash, cash equivalents, and marketable securities as of March 31, 2026, will fund planned operations until at least the second half of 2028.
0 · Reply
bryantboy99
bryantboy99 May. 5 at 10:30 AM
$RCUS https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2026/Arcus-Biosciences-to-Host-Conference-Call-to-Discuss-First-Quarter-2026-Financial-Results-and-Pipeline-Updates/default.aspx
0 · Reply
VAK7
VAK7 May. 5 at 3:36 AM
$HOOD $KRYS $NBIS $RCUS $TGTX That was a very nice summary. And picks. And set me up for 75% 1 yeah performance since 5/4/25. TGTX and HOOD are lagging from this cohort of 5. But not for long. Imho TGTX will be over $45 this year; and HOOD will be in triple digits, no doubt about it. I could have done better, but, to my defense, MW should have sold TGTX before summer 2025; I told myself that if he does not do that, or buy out EU rights, i will reduce my TGTX position before 2 year term to buyback EU rights lapses. And I did not. Price you pay for your own indecisiveness.
0 · Reply
bryantboy99
bryantboy99 May. 1 at 3:18 PM
$AUPH Come on Kevin, we need to get back on track and join my other bio's going to the moon $ETON and $RCUS while I patiently wait for $CTMX to catch up.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 1 at 1:35 AM
$RCUS RSI: 63.04, MACD: 0.8259 Vol: 1.30, MA20: 23.82, MA50: 22.49 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LiveCommander
LiveCommander Apr. 22 at 11:04 PM
$RCUS nice breakout
0 · Reply
JazzyJ03
JazzyJ03 Apr. 22 at 3:19 PM
$RCUS
0 · Reply
bryantboy99
bryantboy99 Apr. 22 at 3:08 PM
$AUPH Come on Tang, gonna need Auph to catch up to $RCUS if you don't mind.
0 · Reply
bryantboy99
bryantboy99 Apr. 22 at 2:37 PM
$RCUS
0 · Reply
RunnerSignals
RunnerSignals Apr. 21 at 8:32 PM
market warriors $HRMY $RCUS $ANNA $BNTX $REI flipped red to green HRMY 5.8x vol and RCUS 3.3x show real accumulation, BNTX solid follow-through; REI ANNA lighter suggest mixed short covering
0 · Reply
stcks
stcks Apr. 21 at 8:08 PM
$RCUS Merck and Eisai’s Phase 3 LITESPARK-012 trial (also called MK-6482-012) tested two experimental triplet regimens in previously untreated patients with advanced ccRCC: • KEYTRUDA (pembrolizumab) + LENVIMA (lenvatinib) + WELIREG (belzutifan, Merck’s HIF-2α inhibitor) • Or a coformulation of KEYTRUDA + quavonlimab (an anti-CTLA-4) + LENVIMA Both arms failed to beat the control arm of KEYTRUDA + LENVIMA alone on the dual primary endpoints of progression-free survival (PFS) and overall survival (OS) at a pre-specified interim analysis. Safety was consistent with prior data, but the regimens did not show added benefit. • Broader implications: It reinforces that simply piling on more agents to the established KEYTRUDA + LENVIMA backbone doesn’t automatically improve outcomes in frontline RCC. This shifts focus back to other mechanisms, lines of therapy, and competitors in the HIF-2α space.
1 · Reply
stcks
stcks Apr. 21 at 8:00 PM
$RCUS Merck’s new kidney cancer combos failed in Phase 3, missing key goals.
0 · Reply
notreload_ai
notreload_ai Apr. 21 at 7:40 PM
$MRK new kidney cancer combos failed in Phase 3, missing key goals; analysts see mixed impact for $RCUS and its drug. https://notreload.xyz/xy/merck-litespark-012-miss-boost-for-arcus/
0 · Reply
bryantboy99
bryantboy99 Apr. 21 at 7:04 PM
$RCUS market must like this news and possible implications for RCUS. https://www.biopharmadive.com/news/merck-welireg-1l-renal-cell-carcinoma-study-results/818093/
0 · Reply
grandefappuccino
grandefappuccino Apr. 20 at 8:01 PM
$RCUS ooooof
0 · Reply
notreload_ai
notreload_ai Apr. 20 at 7:53 PM
$RCUS stops a lung cancer trial early after poor outlook, ends a partner study, and gains more control as $GILD scales back the deal. https://notreload.xyz/xy/rcus-halts-star-121-phase-3-trial-gilead-update/
0 · Reply
TwongStocks
TwongStocks Apr. 20 at 12:04 PM
$RCUS SEC filing, RCUS announces discontinuation of the Phase 3 STAR-121 study due to futility. STAR-121, along with the Phase 2 EDGE-Lung study, will be discontinued. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001724521/000172452126000021/rcus-20260420.htm
0 · Reply
DefenseMania
DefenseMania Apr. 17 at 12:15 PM
$RCUS $GILD coming for RCUS this year ?
0 · Reply
vjtweet
vjtweet Apr. 14 at 10:00 PM
$RCUS has a position for few days.. To add more tomorrow.
0 · Reply
stcks
stcks Apr. 8 at 8:07 PM
$RCUS The next clinical data readouts for Arcus Biosciences ($RCUS), primarily focused on its lead asset casdatifan (a HIF-2α inhibitor for clear cell renal cell carcinoma/ccRCC), are expected in the second half of 2026.
1 · Reply